ESPR Insider Trading Activity and SEC Form 4 Filings
ESPR insider trading summary
Over the past 12 months, insiders at Esperion Therapeutics, Inc. (ESPR) reported 10 sales worth $576K by 3 insiders and no open-market purchases on SEC Form 4. Net insider selling was $576K.
Latest ESPR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Benjamin Looker | Chief Legal Officer | Sell | $37K (11,824 @ $3.15) |
| Jun 17, 2026 | Sheldon L. Koenig | President and CEO | Sell | $169K (53,588 @ $3.15) |
| Jun 17, 2026 | Benjamin Halladay | Chief Financial Officer | Sell | $34K (10,773 @ $3.15) |
| Mar 17, 2026 | Sheldon L. Koenig | President and CEO | Sell | $70K (25,578 @ $2.72) |
| Mar 17, 2026 | Benjamin Halladay | Chief Financial Officer | Sell | $17K (6,424 @ $2.71) |
| Mar 17, 2026 | Benjamin Looker | Chief Legal Officer | Sell | $15K (5,708 @ $2.70) |
| Jan 20, 2026 | Benjamin Looker | General Counsel | Sell | $5K (1,689 @ $2.88) |
| Dec 17, 2025 | Sheldon L. Koenig | President and CEO | Sell | $177K (48,244 @ $3.67) |
| Dec 17, 2025 | Benjamin Looker | General Counsel | Sell | $24K (6,517 @ $3.67) |
| Dec 17, 2025 | Benjamin Halladay | Chief Financial Officer | Sell | $27K (7,337 @ $3.67) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.